Research

Energy balance

Experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce.

Further research is needed to establish the efficacy and safety of GLP-1 agonists in this specific population.

StrongSupportsmedium confidence
Although experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce.
Eva Vilarrasa et al. · Actas Dermo-Sifiliográficas · 2023

Why this rating

The claim is based on the authors' review of existing literature.

Source

[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases

Eva Vilarrasa et al. · Actas Dermo-Sifiliográficas · 2023

DOI 10.1016/j.ad.2023.10.019

reviewCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →